Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021

 Genentech Presents New Data of Ocrevus (ocrelizumab) for Relapsing and Primary Progressive Multiple Sclerosis at AAN2021

Genentech’s Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Shots:

  • The interim analysis of open-label P- IIIb ENSEMBLE study of Ocrevus (ocrelizumab) showed 85% of patients achieved no evidence of disease activity in early-stage RRMS, low annualized relapse rate, improvement in EDSS score
  • The post-hoc analysis of P-III ORATORIO study of Ocrevus vs PBO showed slow loss of brain tissue within T2 MRI lesions in PPMS @120wks.
  • In a 2yrs. US claims analysis, 80% of patients with twice-yearly (6mos.) dosing of Ocrevus showed highest adherence and persistence rates vs other DMTs showed, 75% of patients persist with therapy @2yrs.

Click here to­ read full press release/ article | Ref: Business Wire | Image: Lassonde Entrepreneur Institute

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post